"To my knowledge this registry is the first of its kind in a global sense. From (USHIFU's) perspective, this registry will give participating physicians all across the world larger sets of data to draw from."

— Amanda Willis, a spokeswoman for USHIFU discussing the new Sonablate International high-intensity focused ultrasound (HIFU) registry which is expected to contain information on nearly 6,000 patients across the U.S. and around the globe who have been treated with the company's Sonoblate 500 prostate cancer therapy that uses ultrasound, "Registry gathering data on Sonablate for prostate cancer," pp. 1, 6.